BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 27
• 28
• 29
• 30
• 31

• Business

  Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights

  Adverum Biotechnologies, Inc., a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, reported financial results for the first quarter of 2024.

  May 9, 2024

   · 

  9 min read
• Drug Development

  MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data

  MacroGenics, Inc. provided an update on its recent corporate progress and reported financial results for the quarter ended March 31, 2024.

  May 9, 2024

   · 

  16 min read
• Business

  Interpace Biosciences Announces First Quarter 2024 Financial and Business Results

  Interpace Biosciences, Inc. announced financial results for the first quarter ended March 31, 2024 and provided a business and financial update.

  May 9, 2024

   · 

  9 min read
• Business

  Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update

  Clearside Biomedical, Inc., a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space, reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

  May 9, 2024

   · 

  8 min read
• Business

  Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights

  Invivyd, Inc., a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, announced financial results for the quarter ended March 31, 2024, and recent business highlights.

  May 9, 2024

   · 

  16 min read
• Business

  eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

  eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors for the treatment of cancer, reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

  May 9, 2024

   · 

  12 min read
• Genetown

  Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results

  Dianthus Therapeutics, Inc. reported financial results for the first quarter ending March 31, 2024, and provided an update on recent business achievements.

  May 9, 2024

   · 

  10 min read
• Business

  Gritstone bio Reports First Quarter 2024 Financial Results and Provides Corporate Updates

  Gritstone bio, Inc., a clinical-stage biotechnology company working to develop the world’s most potent vaccines, reported financial results for the first quarter ended March 31, 2024 and provided recent corporate and clinical updates.

  May 9, 2024

   · 

  12 min read
• Business

  Ginkgo Bioworks Reports First Quarter 2024 Financial Results

  Ginkgo Bioworks Holdings, Inc., which is building the leading platform for cell programming and biosecurity, announced its results for the first quarter ended March 31, 2024.

  May 9, 2024

   · 

  19 min read
• Business

  Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent Updates

  Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

  May 9, 2024

   · 

  8 min read